Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Psoriasis

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Am J Clin Dermatol.

Singh S, Kalb RE, de Jong EMGJ, Shear NH, Lebwohl M, Langholff W, Hopkins L, Srivastava B, Armstrong AW

doi: 10.1007/s40257-

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Psoriasis

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Am J Clin Dermatol.

Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M

doi: 10.1007/s40257-017-0274-0.

Psoriasis

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis

J Am Acad Dermatol.

Langley RG, Poulin Y, Srivastava B, Lafferty KP, Fakharzadeh S, Langholff W, Augustin M

doi: 10.1016/j.jaad.2020.08.032.

Psoriasis

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study

J Eur Acad Dermatol Venereol.

Richard MA, Lacour JP, Konstantinou MP, Ruer-Mulard M, Joly P, Aractingi S, Auquier P, Pelvet B, Augustin ML, Mahé E, Chalmers RJG

doi: 10.1111/jdv.16893.

Psoriasis

Reproductive patterns and maternal and pregnancy outcomes in women with psoriasis-A population-based study

J Am Acad Dermatol.

Lambe M, Bergstrom AV, Johansson ALV, Weibull CE

doi: 10.1016/j.jaad.2019.05.099.

Psoriasis

Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

Acta Derm Venereol.

Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C

doi: 10.2340/00015555-3245.

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

Psoriasis

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials

JAMA Dermatol

Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB

doi: 10.1001/jamadermatol.2020.3617

Related content

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study

Reproductive patterns and maternal and pregnancy outcomes in women with psoriasis-A population-based study

Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials